Global Helicobacter Pylori Diagnostics Market Growth (Status and Outlook) 2019-2024

Helicobacter pylori (H. pylori) is a Gram-negative, microaerobic human pathogen and H. pylori infection is strongly related with many gastroduodenal diseases including chronic active gastritis, peptic ulcer diseases, atrophic gastritis, mucosa associated lymphoid tissue (MALT) lymphoma and noncardia gastric cancer. H. pylori infection affects more than half of the adult population worldwide, but the prevalence of H pylori infection varies widely by geographic area, age, race, and socioeconomic status. Usually, the prevalence of H. pylori increases with age in most countries, however a decline in prevalence of H. pylori infection has been observed in recent decades in time trend analysis of several large populations. More than 80% of peptic ulcer diseases are caused by H. pylori infection and the estimated lifetime risk for peptic ulcer disease in H. pylori-infected patients is approximately 15%. Gastric cancer is the third leading cause of cancer-related death worldwide and H. pylori infection is responsible for 74.7% of all noncardia gastric cancer cases. Gastric cancer and peptic ulcer together cause more than a million deaths per year in the world and H. pylori infection always is an important health issue. Various diagnostic methods are developed to detect H. pylori infection and diagnostic tests with both high sensitivity and specificity, exceeding 90%, are necessary for accurate diagnosis of H. pylori infection in clinical practice. Although many diagnostic tests are available now, each method has its own advantages, disadvantages, and limitations. The choice of one method or another could be depended on availability and accessibility of diagnostic tests, level of laboratories, clinical conditions of patients, and likelihood ratio of positive and negative tests on different clinical circumstances. Diagnostic tests are usually divided into invasive (endoscopic-based) and noninvasive methods. Invasive diagnostic tests include endoscopic image, histology, rapid urease test, culture, and molecular methods. Non-invasive diagnostic tests included Non-invasive Techniques, stool antigen test, serological, and molecular examinations.
One of the key drivers witnessed in the market is the growing cost-effectiveness of diagnosis and personalized antibiotic therapy. H. pylori bacteria causes ulcer. H. pylori infection requires antibiotic therapy that includes 10-14 days treatment regimen. This treatment regimen comprises of one or two antibiotics such as amoxicillin, tetracycline, metronidazole, or clarithromycin in combination with ranitidine bismuth citrate, bismuth subsalicylate, and a proton pump inhibitor (PPI). Ulcer-related symptoms such as abdominal pain and nausea and inflammation of gastric mucosa can be cured using PPIs or H2 blockers in combination with antibiotics. The cost-effectiveness of antibiotics and the lesser duration of treatment boosts the adoption of antibiotic regimen by healthcare professionals. This in turn, will drive the demand for pre- and post-monitoring tests.

In terms of geography, the Europe accounted for the majority market shares during 2017 and this mainly accounted to the growing prevalence of peptic ulcer disease and gastritis. The increasing patient pool looking for the early detection of symptoms and treatment is boosting the demand for helicobacter pylori diagnostics in the region. Owing to the continuous efforts of vendors to develop a vaccination for H. pylori infection and the introduction of improved diagnostic techniques, the market will continue to witness considerable growth in this region during the next four years as well.

The helicobacter pylori diagnostics market is characterized by the presence of major vendors and is highly competitive. These vendors compete against each other based on factors including pricing, product differentiation, and advancements in technology. Vendors are highly focusing on expanding their product portfolio and increasing investments in acquiring other players, which will help them increase their revenue shares. Additionally, they are also focusing on the development of vaccines and enhancing their presence in the regional and untapped markets.

Hospitals and clinics reduce the overall disease burden and promote health by offering immunoassays and molecular diagnostic techniques. These techniques enable the early diagnosis of infectious and lethal diseases. The patient pool suffering from infectious diseases such as bacterial diseases (enteric bacteria), cancer, and other life-threatening diseases highly rely on hospitals since they have tie-ups with research and developmental centers and research institutes.


According to this study, over the next five years the Helicobacter Pylori Diagnostics market will register a 7.6% CAGR in terms of revenue, the global market size will reach US$ 740 million by 2024, from US$ 480 million in 2019. In particular, this report presents the global revenue market share of key companies in Helicobacter Pylori Diagnostics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Helicobacter Pylori Diagnostics market by product type, application, key companies and key regions.

This study considers the Helicobacter Pylori Diagnostics value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Invasive Techniques
Non-invasive Techniques
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals and Clinics
Diagnostic Laboratories

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Sekisui Diagnostics
F. Hoffmann-La Roche
Medline Industries
Meridian Bioscience
Bio-Rad Laboratories
Thermo Fisher Scientific
Alpha Laboratories
EKF Diagnostics
Quidel
Halyard Health, Inc
Cardinal Health
Beckman Coulter Inc
Agilent Technologies
Coris BioConcept

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Helicobacter Pylori Diagnostics market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Helicobacter Pylori Diagnostics market by identifying its various subsegments.
Focuses on the key global Helicobacter Pylori Diagnostics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Helicobacter Pylori Diagnostics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Helicobacter Pylori Diagnostics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.